Hematology

Articles:
19 Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61495-1/fulltext

18 Age of Transfused Blood in Critically Ill Adults.
http://www.nejm.org/doi/full/10.1056/NEJMoa1500704

17 An early stage in mouse blood development is reconstructed from gene expression data on thousands of single cells.
http://www.nature.com/nbt/journal/v33/n3/abs/nbt.3154.html

16 A synthetic fibrin cross-linking polymer for modulating clot properties and inducing hemostasis.
http://stm.sciencemag.org/content/7/277/277ra29

15 Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis.
http://www.nejm.org/doi/full/10.1056/NEJMoa1405760

14 Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera.
http://www.nejm.org/doi/full/10.1056/NEJMoa1409002

13 Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera.
http://www.nejm.org/doi/full/10.1056/NEJMoa1409002

12 Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome.
http://www.nejm.org/doi/full/10.1056/NEJMoa1312890

11 Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B.
http://www.nejm.org/doi/full/10.1056/NEJMoa1305074

10 Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms.
http://www.nejm.org/doi/full/10.1056/NEJMoa1311347

9 A Dominant-Negative GFI1B Mutation in the Gray Platelet Syndrome.
http://www.nejm.org/doi/full/10.1056/NEJMoa1308130

8 CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation.
http://www.nejm.org/doi/full/10.1056/NEJMoa1303688

7 Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism.
http://www.nejm.org/doi/full/10.1056/NEJMoa1306638

6 High levels of CD34+CD38low/−CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang (GOELAMS) study.
http://www.haematologica.org/content/96/12/1792.abstract

5 The NOTCH pathway contributes to cell fate decision in myelopoiesis.
http://www.haematologica.org/content/96/12/1753.abstract

4 From stem cell to red cell: regulation of erythropoiesis at multiple levels by multiple proteins, RNAs, and chromatin modifications.
http://bloodjournal.hematologylibrary.org/content/118/24/6258.abstract

3 Bortezomib-induced “BRCAness” sensitizes multiple myeloma cells to PARP inhibitors.
http://bloodjournal.hematologylibrary.org/content/118/24/6368.abstract

2 Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study.
http://bloodjournal.hematologylibrary.org/content/118/24/6284.abstract

1 Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia.
http://bloodjournal.hematologylibrary.org/content/118/24/6310.abstract

Free Images for Presentation: sunipix SUNIPIX